MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection

References

• Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of turbecle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med.37, 509–513 (1937).
   Google Scholar
• Hilleman MR. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Med. Virol.8, 131–182 (1966).
   PubMedGoogle Scholar
• Jansen T, Hofmans MP, Theelen MJ, Schijns VE. Structure–activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine23(8), 1053–1060 (2005).
   PubMed Web of Science ®Google Scholar
• Salk JE, Laurent AM, Bailey ML. Direction of research on vaccination against influenza; new studies with immunologic adjuvants. Am. J. Public Health41(6), 669–677 (1951).
   Google Scholar
• Edelman R. Vaccine adjuvants. Rev. Infect. Dis.2(3), 370–383 (1980).
   PubMedGoogle Scholar
• Page W. Long-term follow-up of army recruits immunized with Freund’s incomplete adjuvanted vaccine. Vaccine Res.2, 141–149 (1993).
   Google Scholar
• Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines1(1), 111–118 (2002).
   PubMed Web of Science ®Google Scholar
• Audran R, Cachat M, Lurati F et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun.73(12), 8017–8026 (2005).
   PubMed Web of Science ®Google Scholar
• Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol Methods95(2), 157–168 (1986).
   Google Scholar
• Vogel FR, Powell MF. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA 141–228 (1995).
   Google Scholar
• Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun.59(4), 1317–1325 (1974).
   PubMed Web of Science ®Google Scholar
• Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun.51(3), 816–825 (1986).
   PubMed Web of Science ®Google Scholar
• Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol.7(12), 1250–1257 (2006).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Edelman R. New Generation Vaccines. Levine MM, Kaper JB, Rappuoli R, Liu M, Good M (Eds). Marcel Dekker, Inc., NY, USA (2004).
   Google Scholar
• Wintsch J, Chaignat CL, Braun DG et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis.163(2), 219–225 (1991).
   PubMed Web of Science ®Google Scholar
• Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine11(9), 909–913 (1993).
   PubMed Web of Science ®Google Scholar
• Keefer MC, Graham BS, McElrath MJ et al. Safety and immunogenicity of Env 2–3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses12(8), 683–693 (1996).
   PubMed Web of Science ®Google Scholar
• Kahn JO, Sinangil F, Baenziger J et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis.170(5), 1288–1291 (1994).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine13, 1557–1562 (1995).
   PubMed Web of Science ®Google Scholar
• Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine15(16), 1710–1715 (1997).
   PubMed Web of Science ®Google Scholar
• Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine14(6), 478–484 (1996).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds.) Plenum Press, NY, USA 277–296 (1995).
   Google Scholar
• Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine18(5–6), 434–439 (1999).
   PubMed Web of Science ®Google Scholar
• Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol.153(9), 4029–4039 (1994).
   PubMed Web of Science ®Google Scholar
• Ott G. Vaccine Adjuvants: preparation methods and research protocols. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O’Hagan D (Ed.). Humana Press, NJ, USA (2000).
   Google Scholar
• Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis.174(6), 1168–1175 (1996).
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2(2), 197–203 (2003).
   PubMedGoogle Scholar
• Podda A, Del Giudice G, O’Hagan DT. MF59: a safe and potent adjuvant for human use. In: Immunopotentiators in Modern Vaccines. Schijns V, O’Hagan DT (Eds). Elsevier Press, USA 149 (2006).
   Google Scholar
• Singh M, Ugozzoli M, Kazzaz J et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine24(10), 1680–1686 (2006).
   PubMed Web of Science ®Google Scholar
• Granoff DM, McHugh YE, Raff HV, Mokatrin AS, Van Nest GA. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immun.65(5), 1710–1715 (1997).
   PubMed Web of Science ®Google Scholar
• Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine4(1), 38–44 (1986).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19(17–19), 2673–2680. (2001).
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine19(25–26), 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol.17(2), 135–140 (2001).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology49(3), 177–184 (2003).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea A, Gonzalez Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine23(3), 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol. Infect.133(4), 687–693 (2005).
   PubMed Web of Science ®Google Scholar
• Iorio AM, Francisci D, Camilloni B et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine21(25–26), 3629–3637 (2003).
   PubMed Web of Science ®Google Scholar
• Paschke R, Pollok M, Geiger H, Ketteler M, Abendroth D, Gunther M. Increased immunogenicity with an MF-59 adjuvanted influenza vaccine compared with a conventional subunit vaccine in renal transplant recipients. J. Prev. Med. Hyg.44, 79–84 (2003).
   Google Scholar
• Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine25(20), 3955–3961 (2007).
   PubMed Web of Science ®Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine17, 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J. Clin. Immunol.27(5), 542–547 (2007).
   PubMed Web of Science ®Google Scholar
• D’Agosto V, Berardi S, Burroni D, Hennig R. Tolerability and safety of an MF59-adjuvanted subunit influenza vaccine (FLUAD®). IVW 2006 – The Second International Conference on Influenza Vaccines for the World, 18–20 October (2006).
   Google Scholar
• Schultze V, D’Agosto V, Wack A et al. Safety of MF59 adjuvant. Vaccine (2007) (In Press).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Fragapane E, Bugarini R et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol.13(9), 1010–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholson K, Colegate A, Podda A et al. Confronting a potential H5N1 pandemic: a randomised controlled trial of conventional and MF59 adjuvanted influenza A/Duck/Singapore/97 (H5N3) surface antigen vaccine. Lancet9272, 357 (2001).
   Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine21(15), 1687–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis.43(9), 1135–1142 (2006).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Bugarini R et al. Cross reactivity to highly pathogenic avian influenza H5N1 viruses following vaccination with non-adjuvanted and MF-59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191 (2005).
   Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine17(22), 2769–2778 (1999).
   PubMed Web of Science ®Google Scholar
• Langenberg AG, Burke RL, Adair SF et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann. Intern. Med.122(12), 889–898 (1995). Published erratum appears in Ann. Intern. Med.123(5), 395 (1996).
   PubMed Web of Science ®Google Scholar
• Corey L, Langenberg AG, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA282(4), 331–340 (1999).
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J.21(2), 133–138 (2002).
   PubMed Web of Science ®Google Scholar
• Borkowsky W, Wara D, Fenton T et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J. Infect. Dis.181(3), 890–896 (2000).
   PubMed Web of Science ®Google Scholar
• Cunningham CK, Wara DW, Kang M et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis.32(5), 801–807 (2001).
   PubMed Web of Science ®Google Scholar
• McFarland EJ, Borkowsky W, Fenton T et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis.184(10), 1331–1335 (2001).
   PubMed Web of Science ®Google Scholar
• Ott G. Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, NY, USA (1995).
   Google Scholar
• Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin. Biol. Ther.4(6), 937–946 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Kazzaz J et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine20(27–28), 3389–3398 (2002).
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T cell responses to influenza vaccine. Vaccine (2007) (In Press).
   PubMed Web of Science ®Google Scholar
• Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J. Infect. Dis.170(5), 1110–1119 (1994).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ugozzoli M, Barackman J et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine18(17), 1793–1801 (2000).
   PubMed Web of Science ®Google Scholar
• Cherpelis S, Shrivastava I, Gettie A et al. DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques. J. Virol.75(3), 1547–1550 (2001).
   PubMed Web of Science ®Google Scholar
• Otten GR, Schaefer M, Greer C et al. Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J. Virol.77, 6087–6092 (2003).
   PubMed Web of Science ®Google Scholar
• Otten G, Schaefer M, Doe B et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine22(19), 2489–2493 (2004).
   PubMed Web of Science ®Google Scholar
• Otten GR, Schaefer M, Doe B et al. Potent immunogenicity of an HIV-1 gag–pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine24, 4503–4509 (2005).
   PubMed Web of Science ®Google Scholar
• Otten GR, Schaefer M, Doe B et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming–boosting regimen with recombinant proteins. J. Virol.79(13), 8189–8200 (2005).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Dong C et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine23(5), 672–680 (2004).
   PubMed Web of Science ®Google Scholar
• AIDS. Vaccine Evaluation Group 022 Protocol Team: cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis.183(4), 563–570 (2001).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis.185(5), 686–690 (2002).
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Florese RH, Peng B et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J. Acquir. Immune Defic. Syndr.43(3), 270–277 (2006).
   PubMed Web of Science ®Google Scholar
• Daems R, Del Giudice G, Rappuoli R. Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine23(50), 5732–5742 (2005).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar